Repeated implantation of interstitial chemotherapy to treat malignant gliomas

Neurosurgery Quarterly

Volumn 18, Issue 4, 2008, Pages 286-289

  Krzeminski, Joseph P ^a   Piquer, Josep ^b   Riesgo, Pedro ^b  

^a York Neurosurgical Associates   (United States)

^b HOSPITAL DE LA RIBERA   (Spain)

Author keywords

Carmustine (BCNU); Gliadel Wafer; Interstitial chemotherapy; Recurrent glioma

Indexed keywords

ANTICONVULSIVE AGENT; CARMUSTINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CRANIOTOMY; DRUG DELIVERY SYSTEM; DRUG IMPLANTATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; GRAND MAL SEIZURE; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION DOSE; REPEAT PROCEDURE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RECURRENCE; WOUND HEALING IMPAIRMENT;

EID: 67249140504     PISSN: 10506438     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNQ.0b013e3181823144     Document Type: Article

References (29)

1. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293:557-564.
2. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neurooncology. 2002;4:278-299.
3. Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus. 2006;20:E3.
4. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
5. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585.
6. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
8. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 2001;35:161-204.
9. Feun LG, Savaraj N, Landy HJ. Drug resistance in brain tumors. J Neurooncol. 1994;20:165-176.
10. Fine HA, Antman KH. High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant. 1992;10:315-321.
11. Wolff SN, Phillips GL, Herzig GP. High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system. Cancer Treat Rep. 1987;71:183-185.
12. Fernandez-Hidalgo OA, Vanaclocha V, Vieitez JM, et al. High-dose BCNU and autologous progenitor cell transplantation given with intra-arterial cisplatinum and simultaneous radiotherapy in the treatment of high-grade gliomas: benefit for selected patients. Bone Marrow Transplant. 1996;18:143-149.
13. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004;63:1281-1284.
14. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345: 1008-1012.
15. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997;41:44-48.
16. Westphal M, Hilt DC, Bortey E, et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology. 2003;5:79-88.
17. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148:269-275.
18. Brell M, Ibanez J, Caral L, et al. Factors influencing surgical complications of intra-axial brain tumours. Acta Neurochir (Wien). 2000;142:739-750.
19. Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg. 2003;98:1175-1181.
20. Dirks P, Bernstein M, Muller PJ, et al. The value of reoperation for recurrent glioblastoma. Can J Surg. 1993;36:271-275.
21. Tenney JH, Vlahov D, Salcman M, et al. Wide variation in risk of wound infection following clean neurosurgery. Implications for perioperative antibiotic prophylaxis. J Neurosurg. 1985;62:243-247.
22. Korinek AM. Risk factors for neurosurgical site infections after craniotomy: a prospective multicenter study of 2944 patients. The French Study Group of Neurosurgical Infections, the SEHP, and the C-CLIN Paris-Nord. Service Epidemiologie Hygiene et Prevention. Neurosurgery. 1997;41:1073-1079.
23. Chopko B, Golden GA, Meldorf M. PROLONG® (Prospective Look at Outcomes Nationally with Gliadel®: report on patient care practices with Gliadel® implantation in brain cancer. Abstract Presented at the 54th Annual Meeting of the Congress of Neurological Surgeons, San Francisco, California, October 16-21, 2004. Available at: http://abstracts.neurosurgeon.org/view. php?id= 12328. Accessed June 25, 2007.
24. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886-1893.
25. Griswold DP Jr. Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence. Cancer Treat Rep. 1986;70:81-86.
26. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res. 1998;58:672-684.
27. Golden GA, Meldorf M; the PROLONG Study Group. Patients with metastatic brain cancer, undergoing resection and Gliadel® implantation experienced low local recurrence rates in the PROLONG® Registry. Presented at the annual meeting of the Society of Neuro-Oncology Toronto, Canada; November 18-21, 2004. Abstract TA-25. 2004.
28. Brem S, Staller A, Wotoczek-Obadia M, et al. Interstitial chemotherapy for local control of CNS metastases. Presented at the annual meeting of the Society of Neuro-Oncology, Toronto, Canada; November 18-21, 2004. Abstract TA-06. 2004.
29. Ewend MG, Brem S, Gilbert M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res. 2007;13:3637-3641.